Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
Alnylam Pharmaceuticals (ALNY) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Alnylam Pharmaceuticals's actual EPS was -$0.01, beating the estimate of -$1.05 per share, resulting in a 99.05% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
